Document:

Exhibit 10.2

THE COMMON STOCK  ISSUABLE  PURSUANT TO THIS  AGREEMENT HAS NOT BEEN  REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED,  OR ANY STATE  SECURITIES LAW. THE
COMMON STOCK ISSUABLE  PURSUANT TO THIS  AGREEMENT MAY NOT BE SOLD,  OFFERED FOR
SALE,  PLEDGED OR  HYPOTHECATED  IN THE ABSENCE OF A  REGISTRATION  STATEMENT IN
EFFECT UNDER SUCH ACT AND SUCH LAWS WITH  RESPECT TO THE COMMON  STOCK  ISSUABLE
PURSUANT TO THIS AGREEMENT, OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY
THAT SUCH REGISTRATION IS NOT REQUIRED.

                              CAVIT SCIENCES, INC.
                         COMMON STOCK PURCHASE AGREEMENT

INFORMATION REGARDING CAVIT SCIENCES, INC., INCLUDING ITS PROSPECTUS,  FORM 10SB
REGISTRATION AND RELATED FILINGS UNDER THE SECURITIES ACTS OF 1933 AND 1934, ARE
AVAILABLE FOR REVIEW ON THE SEC'S WEBSITE ( WWW.SEC.GOV ) AND ON CAVIT SCIENCES,
INC.'S WEBSITE ( WWW.CAVITSCIENCES.COM ).

     This COMMON STOCK PURCHASE AGREEMENT ("Agreement") is made this 29th day of
November  2007 by and  between  CAVIT  SCIENCES,  INC.,  a  Florida  corporation
("CAVIT" or the "Company"),  and Isthmus Investments  Management S.A. ("Isthmus"
or "Investor").

                                   Background

     As more fully set forth  herein,  Investor has agreed to purchase  from the
Company  shares of Common Stock  ("Common  Stock") and warrants for common stock
("Warrants") for a purchase price of $250,000. ("Commitment Amount").
Agreement

     NOW, THEREFORE,  intending to be legally bound hereby, the parties agree as
follows:

     1. Commitment.  Subject to the terms and conditions hereof, Investor agrees
to purchase  1,250,000  shares of Cavit's  Common Stock from Cavit at a purchase
price of $.20 per share and  1,500,000  warrants  for  Cavit's  Common  Stock at
strike  prices  ranging  from $.40 to $3.00 per share  (see  table  below)  with
varying   expiration   dates  (see  table  below)  from  the  date  of  issuance
("Commitment Purchase Amount") not to exceed the Commitment Amount.

TABLE: The number of warrants, class of warrants, exercise price of warrants and
term of warrants are set forth below:

     Class     No. of Warrants           Exercise Price            Term
     -----     ---------------           --------------            ----

       A            125,000             $ .40 per share           6 months
       B            125,000             $ .60 per share           9 months
       C            125,000             $ .80 per share          12 months
       D            175,000             $1.00 per share          15 months
       E            175,000             $1.25 per share          18 months
       F            175,000             $1.50 per share          21 months
       G            175,000             $1.75 per share          24 months
       H            250,000             $2.00 per share          36 months
       I            175,000             $3.00 per share          48 months

     2. Share  Issuance.  Upon the payment of the  Commitment  Purchase Price as
aforesaid, the Company shall issue and cause to be delivered with all reasonable
dispatch to Investor and in the name of Investor,  a certificate or certificates
for the  number of shares of Common  Stock so  purchased.  Such  certificate  or
certificates shall be deemed to have been issued and Investor shall be deemed to
have become a holder of record of such Common Stock on and as of the date of the
delivery  to the  Company of and  payment of the  Commitment  Purchase  Price as
aforesaid.  If,  however,  at the date of  payment of such  Commitment  Purchase
Price, the transfer books for the Common Stock shall be closed, the certificates
for the Common Stock shall be issued and Investor shall become a record owner of
such  Common  Stock on and as of the  next  date on which  such  books  shall be
opened,  and until such date the  Company  shall be under no duty to deliver any
certificate for such Common Stock.

     3. Warrant Issuance.  Upon the payment of the Commitment  Purchase Price as
aforesaid, the Company shall issue and cause to be delivered with all reasonable
dispatch to Investor  and in the name of  Investor,  warrants  for the number of
warrants for Common Stock so purchased.  Such  warrants  shall be deemed to have
<PAGE>
been  issued and  Investor  shall be deemed to have become a holder of record of
such  warrants  on and as of the  date of the  delivery  to the  Company  of and
payment of the Commitment Purchase Price as aforesaid.

     4.  Representations  by Investor.  Investor  represents and warrants to the
Company as follows:

     a) Investor has relied only upon the information presented and contained in
     the Term Sheet  provided  by the  Company  ("Offering  Materials")  and the
     Investor  has  read  and  understands  the  information  contained  in  the
     Company's Prospectus, Form 10 SB Registration and related filings under the
     Securities Acts of 1933 and 1934,  which are available on the SEC's website
     referred to above. Investor has had the opportunity to ask of the person or
     persons  acting on behalf of the Company any and all relevant  questions in
     connection  with any aspect of the Company  including,  but not limited to,
     the Common Stock offered by the Offering Materials and has received answers
     which  Investor  considers to be reasonably  responsive to such  questions.
     Investor has had the  opportunity to verify the accuracy of the information
     contained in the Offering Materials.

     (b) Investor  understands that Investor is subscribing for the Common Stock
     without  being  furnished any  literature  in connection  with the Offering
     other than the  Offering  Materials,  and that the  Offering  of the Common
     Stock presented in the Offering Materials will not have been scrutinized by
     the Securities and Exchange  Commission or by the securities  administrator
     or  similar  bureau,  agency,  or  department  of the state of  Investor's'
     residence.

     (c) Investor  understands (i) that the Common Stock has not been registered
     under the  Securities  Act of 1933,  as amended  ("Act"),  or registered or
     qualified under the securities laws of the state of Investor's'  residence,
     (ii) Registration Rights: upon receipt of a written demand by the Investor,
     the  Company  is  obligated  to  register  the  shares of Common  Stock and
     warrants  under the  Securities  Act of 1933, as amended,  within limits of
     current SEC guidelines.

     (d) The Common  Stock is being  purchased  for  Investor's  own account for
     investment  purposes  only and not for the interest of any other person and
     is not  being  purchased  with a view to or for the  resale,  distribution,
     subdivision or fractionalization thereof.

     (e) Investor is able to bear the economic  risks related to purchase of the
     Common Stock for an  indefinite  period of time (i.e.,  Investor is able to
     afford a complete  loss of the Common  Stock  Investor  is  subscribing  to
     purchase).  Investor's  net  worth  and  assets  are  sufficient  to enable
     Investor to purchase shares of Common Stock from Cavit in the amount of the
     Commitment Amount pursuant to this Agreement.

     (f)  Investor's  overall  commitment to  investments  which are not readily
     marketable is not  disproportionate  to Investor's net worth and Investor's
     investment in the Company will not cause such overall  commitment to become
     excessive.

     (g) Investor has adequate means of providing for  Investor's  current needs
     and possible personal contingencies.  Investor has no need for liquidity of
     the Common Stock  subscribed  to be  purchased  hereby and has no reason to
     anticipate any change in Investor's  personal  circumstances,  financial or
     otherwise,  which might cause or require any sale or  distribution  of such
     Common Stock subscribed to be purchased.

     (h) Investor  recognizes  that the purchase of the Common Stock  involves a
     high degree of risk including those special risks.

     (i) Investor understands that Investor's right to transfer the Common Stock
     will be restricted as set forth on the  certificate  evidencing  the Common
     Stock. Such restrictions  include  provisions  against transfer unless such
     transfer is not in violation  of the Act, or  applicable  state  securities
     laws (including investor suitability standards).

     (j) All information  which Investor has provided to the Company  including,
     but not  limited  to,  financial  position,  and  status  as an  accredited
     investor,  and knowledge of financial and business matters is true, correct
     and  complete  as of the  date of  execution  of this  Agreement.  Investor
     understands  that the  Company  will  rely in a  material  degree  upon the
     representations contained herein.

                                       2
<PAGE>
     (k)  Investor  understands  that a  legend  may  be  placed  on  any  stock
     certificate  representing  the Common Stock  substantially to the following
     effect:

     On the front side:

     "Transfer of the shares represented by this certificate is restricted - see
     reverse side."

     On the reverse side:

     "The  shares  represented  by this  certificate  have  been  issued  to the
     registered owner in reliance upon written representations that these shares
     have been taken for investment. These shares have not been registered under
     the  Securities  Act of  1933,  as  amended  ("Act"),  and may not be sold,
     transferred or assigned  unless an opinion of counsel  satisfactory  to the
     company  has been  received  by the  company to the effect  that such sale,
     transfer or  assignment  will not be in  violation of the Act and the rules
     and  regulations  promulgated  thereunder  or applicable  state  securities
     laws."

     (l) Investor is an "accredited investor" as defined in Rule 501 promulgated
     under the Act because Investor's  individual net worth (or Investor's joint
     net worth with his spouse) on the date hereof exceeds $1,000,000.

     5.  Securities  Laws.  As a condition  to the  issuance of any Common Stock
pursuant   this   Agreement,   Investor   shall   execute   and   deliver   such
representations,  warranties,  and covenants, that may be required by applicable
federal and state  securities law, or that the Company  determines is reasonably
necessary in connection with the issuance of such Common Stock. In addition, the
certificates  representing  the Common  Stock shall  contain  such  legends,  or
restrictive  legends,  or stop  transfer  instructions,  as shall be required by
applicable Federal or state securities laws, or as shall be reasonably  required
by the Company or its transfer  agent.  The Investor has completed and delivered
an Investor Questionnaire to the Company.

     6.  Binding  Effect.  This  Agreement  shall be  binding  upon the  party's
respective heirs, personal  representatives,  successors and assigns;  provided,
however, that this Agreement shall not be assignable by Investor, in whole or in
part, without the prior consent of the Company.

     7.  Applicable  Law. This  Agreement  shall be deemed to be a contract made
under the laws of the State of Florida and for all  purposes  shall be construed
in accordance with the laws thereof regardless of its choice of law rules.

     8. Brokers and Finders.  Cavit and Investor hereby  represent to each other
that no broker or  finder  has been  employed  or  engaged  by either of them in
connection  with the  transactions  contemplated  in this Agreement and that all
negotiations  relative to this Agreement  have been carried on directly  between
the parties hereto without the intervention of any other person.

     9.  Survival  of  Representations   and  Warranties,   and  Remedies.   All
representations  and warranties  contained in this  Agreement  shall survive the
execution and delivery of this Agreement.

     10. Entire Agreement.  This Agreement  constitutes the entire understanding
and  agreement  between the  parties  hereto  with  respect to the  transactions
contemplated  herein,  supersedes  all  prior  and  contemporaneous  agreements,
understandings,  negotiations and discussions,  whether oral or written,  of the
parties, and there have been no warranties, representations or promises, written
or oral, made by any of the parties hereto except as herein  expressly set forth
herein.

     11. Waiver, Modification, etc. Any party to this Agreement may waive any of
the  terms  or  conditions  of  this  Agreement  or  agree  to an  amendment  or
modification  to this Agreement by an agreement in writing  executed in the same
manner (but not necessarily by the same persons) as this Agreement. No amendment
or modification of this Agreement shall be binding unless in writing executed by
all of the parties to this Agreement. No waiver of any of the provisions of this
Agreement  shall be deemed or shall  constitute a waiver of any other  provision
hereof  (whether or not similar),  nor shall any waiver  constitute a continuing
waiver unless otherwise expressly provided.

                                       3
<PAGE>
     12.  Funding Date. It is the intention of the Investor to begin funding the
Commitment Purchase Price on or before November 30, 2007.

     13.  Notice.  Any  notice or other  communications  required  or  permitted
hereunder shall be sufficiently given: (i) three (3) business days after if sent
by certified mail, return receipt  requested,  postage prepaid,  or (ii) one (1)
business day after sent by Federal Express or other overnight  courier providing
delivery  confirmation for next business day delivery, or (ii) when delivered by
personal delivery, telecopier, or e-mail, in any event delivered to or addressed
as follows:

     If to Investor:

            Isthmus Investments Management S.A.
            P.O. Box 1508
            World Trade Centre, Panama
            Republic of Panama
            Attn: Adam Carmody, President

     If to Cavit:

          Cavit Sciences, Inc.
          100 E. Linton Blvd., Suite 106B
          Delray Beach, Florida 33483
          Attention: Colm J. King, CEO

     14. Counterparts.  This Agreement may be signed in two or more counterparts
which counterparts shall constitute a single,  integrated agreement binding upon
all the signatories to such counterparts. Delivery of an executed counterpart of
this  Agreement  by  facsimile  shall be equally as  effective  as delivery of a
manually executed counterpart of this Agreement.

     15. Expenses.  Except as specifically provided otherwise herein, each party
hereto shall pay its or his own expenses  arising  from this  Agreement  and the
transactions contemplated hereby, including,  without limitation,  all legal and
accounting fees and disbursements;  provided, however, that nothing herein shall
limit or  otherwise  modify any right of the  parties to recover  such  expenses
(including  legal fees and costs of litigation)  from the other in the event any
party hereto breaches this Agreement.

     16. Further Assurances.  Each of the parties hereto shall hereafter execute
and deliver such further  documents and instruments and do such further acts and
things as may be  required or useful to carry out the intent and purpose of this
Agreement and as are not inconsistent with the terms hereof.

        IN WITNESS WHEREOF,  the parties hereto have executed and delivered this
Common Stock Purchase Agreement on the date first written above.

Isthmus Investments Management S.A.              Cavit Sciences, Inc.

By: /s/ Adam Carmody                             By: /s/ Colm J. King
   ---------------------------                      ---------------------------
   Adam Carmody                                  Colm J. King,
   Title: President                              Title: Chief Executive Officer

                                       4Letter Regarding Termination of Employment Agreement

 Exhibit 10.1 
 November 28, 2007 
 Mr. Bruce A. Williamson 
 79 Wincrest Falls 
 Cypress, Texas 77429 
  

	 	Re:	Termination of Employment Agreement and Supplemental Benefits Agreement 

 Dear Bruce: 
 This letter is written to document certain agreements between Dynegy Inc. (“Dynegy”) and you regarding your
employment agreement with Dynegy, dated October 18, 2002, and as subsequently amended (the “Employment Agreement”), and your eligibility to receive certain benefits, as discussed below. 
 I. Employment Agreement  
 Both Dynegy and you have
determined that continued maintenance of your Employment Agreement after the expiration of its current Term (as defined in the Employment Agreement) on December 31, 2007, is no longer required with respect to your employment with Dynegy or one
of its subsidiaries or affiliates (collectively, the “Company”). Accordingly, this letter serves as formal written notice by Dynegy and you, pursuant to Paragraph 2(a) of the Employment Agreement, that both parties have hereby elected to
not extend the Term of the Employment Agreement. As a result, the Employment Agreement will terminate effective December 31, 2007. 
 II.
Supplemental Benefits 
 In addition to the other Company benefits that are otherwise available for officers of the Company, effective
January 1, 2008, you will be eligible to receive the following benefits in accordance with the terms and conditions of this agreement or the particular plan or policy, as applicable: 
 A. Change in Control Severance Benefits 
 For the
period of time that the Second Supplement to the Dynegy Inc. Executive Severance Pay Plan, as currently amended and as the same may be further amended or supplemented from time to time (the “Second Supplement”), remains in effect, and
assuming your continued employment with the Company, you will be eligible to receive, pursuant to this agreement, the severance benefits of a Level One Covered Individual (as defined in the Second Supplement) under the Second Supplement in
accordance with the terms and conditions of the Second Supplement, which are incorporated herein by reference except as such terms and conditions are otherwise modified herein, provided you agree to all such terms and conditions. (In the event the
Second Supplement is replaced by a successor change in control severance plan, you will be eligible to participate in such successor plan.) 

 Mr. Bruce A. Williamson 
 November 28, 2007 
 Page 2 
 You hereby agree to all terms and conditions of the Second Supplement, including but not limited
to, the provisions of Section1 3.5 (Confidentiality/Noncompete/Nonsolicitation), with the following modifications for purposes of this agreement: 

 1. Section 2.1(c)(2) is hereby modified to require a material diminution in your annual base salary from the annual base salary
provided to you immediately prior to the date on which a Change in Control (as defined in the Second Supplement) occurs; 
 2. By your
execution of this agreement, you are eligible to receive the same severance benefits hereunder as a Level One Covered Individual under the Second Supplement who signed the letter described in Section 2.1(h) on or before April 1, 2007;

 3. Upon your entitlement to receive severance benefits hereunder, the lump sum payments described in Subsections 3.1(a) and
(b) shall be paid to you in accordance with the terms and conditions hereof no later than March 15th of the calendar year following the year in which your Involuntary Termination (as defined in the Second Supplement) occurs;

 4. Outplacement services and benefits under Section 3.1(e) will be provided in accordance with Internal Revenue Code
Section 409A and the regulations and guidance issued thereunder (“Code Section 409A”); and 
 5. You are not entitled to
receive a Gross-up Payment (as defined in the Second Supplement) under Section 3.4 (you will be covered under a separate excise tax reimbursement policy of the Company). 
 Each of the payments of severance, continued medical and outplacement benefits provided herein are designated as separate payments for purposes of the
short-term deferral rules under Treasury Regulation Section 1.409A-1(b)(4)(i)(F), the exemption for involuntary terminations under separation pay plans under Treasury Regulation Section 1.409A-1(b)(9)(iii), the exemption for medical
expense reimbursements under Treasury Regulation Section 1.409A-1(b)(9)(v)(B), and the exemption for in-kind benefits under Treasury Regulation Section 1.409A-1(b)(9)(v)(C). As a result, (A) payments that are made on or before the
15th day of the third month of the calendar year following the applicable year of termination, and (B) any additional payments that are made on or before the last day of the second calendar year following the year of your termination and do not
exceed the lesser of two times your base salary in the year prior to your termination or two times the limit under Code Section 401(a)(17) then in effect, are exempt from the requirements of Code Section 409A. All amounts paid to you for
reimbursement of any 
  

	 1
	 All Section references herein shall refer to Sections of the Second Supplement.

  

 2 

 Mr. Bruce A. Williamson 
 November 28, 2007 
 Page 3 
 medical expense will be
paid to you not later than the last day of the calendar year following the year in which you incur such medical expense. Since you are a “specified employee” within the meaning of Code Section 409A, to the extent the payments to be
made during the first six (6)-month period following your termination of employment exceed such exempt amounts or are otherwise subject to the six (6)-month payment delay requirements of Code Section 409A, those payments shall be withheld and
the amount of the payments withheld will be paid in a lump sum, without interest, during the seventh month after your termination. 
 B. Death
Benefits 
 In addition to the death benefits provided by the Company to you, which currently comprise life insurance coverage in the
amount of one times your annual base salary, during your employment with the Company, the Company will reimburse you for the annual premium cost associated with an individual term life policy on your life, with a coverage amount not to exceed One
Million Dollars ($1,000,000.00), which policy shall be purchased and owned by you (or a trust that you may select to own such policy). All premium reimbursement amounts will be paid to you as soon as administratively reasonable but in no event later
than the last day of the calendar year following the year in which you incur such premium cost. 
 In the event of your death, for a period
of twelve (12) months from the date of your death, your family shall be eligible to receive all medical, dental and vision benefits that the Company was maintaining for you and/or your family as of the date of your death, at the same
contribution and premium rates as may be charged to active employees during such period. Such twelve (12)-month period shall run concurrently with the applicable COBRA period. 
 C. Disability Benefits 
 In addition to the
long-term disability benefits provided by the Company to you, which currently comprise salary continuation of up to 60% of your monthly base salary (subject to a monthly maximum of $25,000 pursuant to the terms and subject to the conditions of the
Company’s long-term disability plan, in the event you become Disabled (as defined below) during your employment with the Company, you will receive a lump sum payment equal to twelve (12) months of your Base Salary (as defined below). Such
payment will be paid to you as soon as administratively reasonable but in no event later than the 15th day of the third month of the calendar year
following the year that you are determined to be Disabled. In addition, to the extent that such payment to you results or will result in an offset of any long-term disability payments that are otherwise payable to you under a long-term disability
plan maintained by the Company, the Company shall make an additional lump sum payment to you that is equal to the amount of such offset payments, as soon as administratively reasonable but in no event later than the 15th day of the third month of the calendar year following the year that you are determined to be Disabled. For purposes of this Paragraph C, “Disabled” means that a
determination has been made that you are disabled for purposes of being eligible to receive disability benefits under the Company’s long-term disability plan (or Social Security disability benefits at a time when the 

 

 3 

 Mr. Bruce A. Williamson 
 November 28, 2007 
 Page 4 
 Company does not maintain
a long-term disability plan or such plan is not available to you). For purposes of this Paragraph C, “Base Salary” means your regular base salary on the date you are determined to be Disabled but excluding all bonuses, expense
reimbursements, benefits paid under any plan maintained by the Company and all equity awards of any type. 
 D. Vacation Benefits 
 You are entitled to receive four (4) weeks of paid vacation per annum. 
 E. Tax Withholding 
 Any benefits paid or provided pursuant to this agreement will be subject to the
required tax withholding. 
 F. Section 409A 
 It is the parties’ intention that this agreement will not result in unfavorable tax consequences to you under Code Section 409A. Accordingly, you consent to any amendment of this agreement as Dynegy may reasonably make in
furtherance of such intention, and Dynegy shall promptly provide you with a copy of such amendment. Any such amendments shall be made in a manner that preserves to the maximum extent possible the intended benefits to you. This paragraph does not
create an obligation on the part of Dynegy to modify this agreement and does not guarantee that the amounts or benefits owed under this agreement will not be subject to interest and penalties under Code Section 409A. 
 This agreement shall supercede any and all existing oral or written agreements, representations or warranties between Dynegy and you regarding the
subject matter hereof. Except as otherwise provided herein, this agreement may not be amended except by written agreement of both parties. 
  

 4 

 Mr. Bruce A. Williamson 
 November 28, 2007 
 Page 5 
 This
agreement is executed as of the date first set forth above and effective as set forth herein. 
  

			
	Dynegy Inc.
		
	By:	 	 /s/ J. Kevin Blodgett

		 	J. Kevin Blodgett
		 	 General Counsel and Executive
 Vice President,
Administration

  

	
	Agreed and Accepted:
	
	 /s/ Bruce A. Williamson

	Bruce A. Williamson

  

 5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00133-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00133-of-00352.parquet"}]]